Allogene Therapeutics FCF Conversion
The FCF Conversion Rate (FCF/EBITDA) of Allogene Therapeutics (ALLO) as of Oct 31, 2026 is 78.39 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 78.03 % — a change of 0.46% (higher).
Get this data via API
Financial Data API
FCF Conversion
78.39 %
YoY
0.46%
Last updated:
The Allogene Therapeutics FCF Conversion history
3 Years
10 Years
25 Years
Max
| YEAR | FCF Conversion | YoY |
|---|---|---|
| 78.39 % | +0.46% | |
| 78.03 % | +6.73% | |
| 73.11 % | +6.82% | |
| 68.44 % | -18.76% | |
| 84.24 % | +8.63% | |
| 77.55 % | -23.91% | |
| 101.92 % | +350.16% | |
| 22.64 % | -100.00% | |
| 2.50 M % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Allogene Therapeutics Stock analysis
Frequently Asked Questions about Allogene Therapeutics stock
FCF Conversion Rate (FCF/EBITDA) of Allogene Therapeutics is 78.39 % in 2025.
FCF Conversion Rate (FCF/EBITDA) of Allogene Therapeutics changed from 78.03 % to 78.39 %, representing a 0.46% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Allogene Therapeutics since 2006 – with annual values, charts, and detailed analysis.
FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.
A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Allogene Therapeutics with sector peers and the industry average to assess whether it is attractive.
To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Allogene Therapeutics
All Key Metrics — Allogene Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth